Head-to-head · Cost-Efficiency Index
Peter MD vs NextMeds
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Peter MD
Someone who wants a single telehealth account to also cover TRT, hair loss, ED or NAD+ alongside a GLP-1 script, and who will read past the first-month price before budgeting the ongoing cost.
Visit Peter MDNextMeds
Shoppers who will call out and verify the exact price at checkout, given the site shows several different promo numbers at once.
Visit NextMedsThe verdict
NextMeds takes it, leading the Cost-Efficiency Index 74 to 72. NextMeds is a compounded-GLP-1 telehealth platform naming a real clinical group (Lion MD, led by two NPI-verifiable physicians) and six named compounding pharmacies — unusually transparent on that front. Peter MD still earns a C — Someone who wants a single telehealth account to also cover TRT, hair loss, ED or NAD+ alongside a GLP-1 script, and who will read past the first-month price before budgeting the ongoing cost.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs NextMeds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Peter MD | NextMeds |
|---|---|---|
| Cost-Efficiency Index | 72/100 | 74/100 |
| Semaglutide / mo | $149/mo first-time (Level 1), $139/mo returning (Level 2) | $79/mo (starting dose, promotional rate, compounded) |
| Tirzepatide / mo | $149 first month, then $249/mo billed quarterly | $129/mo (starting dose, promotional rate, compounded) |
| Semaglutide / yr (modeled) | $1,788 | $948 |
| Tirzepatide / yr (modeled) | $2,988 | $1,548 |
| Coverage | Varies by treatment — excluded in several states (marketing pages list AL/ID; the affiliate program's own disclosure is wider) | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #54 | #61 |
Peter MD
72/100Where the value is
- Broadest cross-category catalog in this ranking under one account: TRT, ED, non-GLP-1 weight loss, GLP-1 (semaglutide/tirzepatide), men's hair loss and NAD+, plus sermorelin
- Physician-prescribed, nationwide telehealth brand operating since 2021 (Miami, FL HQ)
- Sermorelin ($585 for a 12-week supply, ~$195/mo) and NAD+ ($369 for an 8-10 week supply, ~$147-184/mo) sit in the same catalog as the GLP-1 line for anyone consolidating multiple scripts
The tradeoffs
- Tirzepatide's $149 first-month rate steps up to $249/mo billed quarterly — the number that matters for budgeting is the renewal price, not the headline
- Semaglutide pricing depends on tier: $149/mo first-time (Level 1) vs $139/mo returning (Level 2), with different total costs ($447 vs $834) over different supply windows, so the all-in cost is not a single number
NextMeds
74/100Where the value is
- Names a real, NPI-verifiable clinical group (Lion MD: Dr. Ana Lisa Carr, Dr. Kelly Tenbrink) rather than an anonymous provider network
- Names six real compounding pharmacies (Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub, Foothills) instead of one generic claim
- Claims and states 'We service all 50 states'
The tradeoffs
- The live site shows at least three different headline promo prices ($69/$79/$89 for semaglutide) concurrently or near-concurrently, with no clear single 'current' number — a real transparency problem
- Aggressive countdown-timer urgency tactics ('Price increases in...', 'OFFER ENDS AUGUST 10TH AT MIDNIGHT!') are used to pressure signup
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.